Assessing Value for Money in Medical Screening

Cairns J Shackley P. Sometimes sensitive, seldom specific: A review of the economics of screening. Health Economics, 1993;2:43–53.

Neuhauser D Lewicki AM . What do we gain from the sixth stool guaiac? N Engl J Med 1975;293:226–8.

Krahn M Gafni A. Discounting in the economic evaluation of health care interventions. Med Care, 1993;31:403–18.

Hagard S Carter F Milne RG . Screening for spina bifida cystica: A cost-benefit analysis. British Journal of Preventive and Social Medicine, 1976;30:40–53.

Layde PM von Allmen SD Oakley GP . Maternal serum alpha-fetoprotein screening: A cost benefit analysis. Am J Public Health, 1979;69:566–73.

Henderson JB . Measuring the benefits of screening for open neural tube defects. J Epidemiol Community Health, 1982;36:214–9.

Henderson JB . An economic appraisal of the benefits of screening for open spina bifida. Soc Sci Med, 1982;16:545–60.

Henderson JB . Economic evaluation of screening for fetal and genetic abnormality. Kings Fund Consensus Conference on Prenatal Screening., London: Kings’ Fund Institute, 1987.

Caiman K Hine D Kendell R Folic acid and neural tube defects: guidelines on prevention., Edinburgh: Scottish Office Home and Health Department, 1992.

Hagard S Carter F. Preventing the birth of infants with Down's syndrome: A cost-benefit analysis. BMJ, 1976;1:753–6.

Wald NJ Cuckle HS Densem JW Maternal serum screening for Down's syndrome in early pregnancy. BMJ, 1988;297:883–7.

Sheldon TA Simpson J. Appraisal of a new scheme for prenatal screening for Down's syndrome. BMJ, 1991;302:1133–6.

Shackley P McGuire A Boyd PA An economic appraisal of alternative prenatal screening programmes for Down's syndrome. J Public Health Med, 1993;15:175–84.

Birch S Donaldson C. Applications of cost-benefit analysis to health care: Departures from welfare economic theory. Journal of Health Economics, 1987;6:211–25.

Mooney G Lange M. Ante-natal screening: What constitutes benefit? Soc Sci Med 1993;37:873–8.

Garber AM Fenerty JP . Costs and benefits of prenatal screening for cystic fibrosis. Med Care, 1991;29:473–89.

Mennie ME Gilfillan A Compton M Couple screening for cystic fibrosis. Lancet, 1992;340:214–6.

Donaldson C Shackley P Abdalla M Miedzybrodzka Z. Willingness to pay for antenatal carrier screening for cystic fibrosis. Health Economics Research Unit discussion paper 04/93., University of Aberdeen, 1993.

Donaldson C. Willingness to pay for publicly provided goods — a possible measure of benefit? Journal of Health Economics 1990;9:103–18.

Gafni A. Willingness-to-pay as a measure of benefits: Relevant questions in the context of public decision making about health care programs. Med Care, 1991;29:1246–52.

Koretz RL . Universal prenatal hepatitis B testing: Is it cost-effective? Obstet Gynecol 1989;74:808–14.

Christian SS Duff P. Is universal screening for hepatitis B infection warranted in all prenatal populations? Obstet Gynecol 1989;74:259–61.

Schalm SW Mazel JA de Gast GC Prevention of hepatitis B infection in newborns through mass screening and delayed vaccination of all infants of mothers with hepatitis B surface antigen. Pediatrics, 1989;83:1041–8.

Kumar ML Dawson NV McCullough AJ . Should all pregnant women be screened for hepatitis B? Ann Intern Med 1987;107:273–7.

Summers PR Biswas MK Pastorek JG Pernoll ML Smith LG Bean BE . The pregnant hepatitis carrier: Evidence favoring comprehensive antepartum screening. Obstet Gynecol, 1987;69:701–4.

Ernest JM Givner LB Pool R. Intrapartum hepatitis B screening in a low-risk population. Am J Obstet Gynecol, 1990;163:978–80.

Arevalo JA Washington AE . Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA, 1988;259:365–9.

Brook MG Lever AML Kelly D Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: Three years experience in a London hospital. QJ Med, 1989;71:313–7.

Adler MW Belsey EM McCutchan JA Mindel A. Should homosexuals be vaccinated against hepatitis B virus? Cost and benefit assessment. BMJ, 1983;286:1621–4.

Jönsson B. Cost-benefit analysis of hepatitis B vaccination. Postgrad Med J, 1987;63:27–32.

Tormans G Van Damme P Carrin G Clara R Eylenbosch W. Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus — the case of Belgium. Soc Sci Med, 1993;37:173–81.